Home › Entities › clinical_trial › Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

clinical trial
MedicalStudy clinical_trial Q61980677
Press Enter · cited answer in seconds

Summary

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma is a clinical trial[1].

Key Facts

  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma is in the country of United States[2].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's instance of is recorded as clinical trial[3].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's start time is recorded as +2009-05-31T00:00:00Z[4].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's end time is recorded as +2011-11-30T00:00:00Z[5].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's sponsor is recorded as Massachusetts General Hospital[6].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's main subject is recorded as lymphoma[7].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's number of participants is recorded as {'unit': '1', 'amount': '+26'}[8].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's title is recorded as Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma[9].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's ClinicalTrials.gov ID is recorded as NCT00869999[11].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's research intervention is recorded as rituximab[12].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's research intervention is recorded as everolimus[13].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's research intervention is recorded as sirolimus[14].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's clinical trial phase is recorded as phase II clinical trial[15].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's research site is recorded as Massachusetts General Hospital[16].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's research subject recruitment status is recorded as completed[17].
  • Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma's study type is recorded as interventional study[18].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.
  17. [18] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Retrieved May 3, 2026, from https://4ort.xyz/entity/everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma
MLA “Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma.
BibTeX @misc{4ortxyz_everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma}}, year = {2026}, url = {https://4ort.xyz/entity/everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma — https://4ort.xyz/entity/everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/everolimus-plus-rituximab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma · Last refreshed: